Anteris Technologies Global Corp. Common Stock

Anteris Technologies Global Corp. Common Stock

AVR · NASDAQ · Healthcare / Medical Devices

5.42USD-0.44 (-7.51%)

Price History

Full chart

Market Stats

Previous Close5.86
Open5.81
Day Range5.35 – 5.81
52-Week Range3.30 – 11.06
Volume1.47M
Market Cap745.56M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.96
Dividend Yield0.00%
Beta0.73
50-Day Avg8.56
200-Day Avg7.17

About

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Wayne Geoffrey Paterson
  • Employees174
  • HeadquartersToowong Tower, Toowong, QLD, Australia, 4066, USA
  • Websitehttps://anteristech.com

Leadership

  • Mr. Wayne Geoffrey PatersonVice Chairman & CEO · b. 1967
  • Mr. David St. DenisPresident & Director · b. 1969
  • Mr. Matthew McDonnellChief Financial Officer · b. 1974

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.46M5.83M3.20M2.73M2.70M1.91M
Growth (%)-+6.83%-45.10%-14.56%-1.16%-29.23%
Cost of Revenue2.10M3.93M2.90M1.86M1.44M2.23M
Gross Profit3.36M1.91M298.38K876.80K1.27M-317.00K
Gross Margin61.53%32.68%9.32%32.06%46.84%-16.57%
Operating Expense16.62M18.77M31.41M49.02M79.64M93.58M
Operating Income-13.26M-16.86M-31.11M-48.14M-78.37M-93.89M
Operating Margin-242.99%-289.18%-972.11%-1760.26%-2899.45%-4908.21%
EBITDA-14.05M-15.50M-29.14M-45.54M-74.38M-92.49M
EBITDA Margin-257.50%-265.79%-910.45%-1665.14%-2751.68%-4834.87%
Net Income-11.78M-17.17M-30.56M-46.02M-76.29M-94.14M
Net Income Margin-215.78%-294.50%-954.91%-1682.81%-2822.46%-4921.28%
R&D3.57M9.99M17.59M31.02M51.45M69.12M
R&D as % of Total Revenue65.47%171.42%549.57%1134.32%1903.48%3613.17%
Interest Expense300.64K1.03M648.71K67.09K82.00K73.00K
Interest Expense % of Total Revenue5.51%17.74%20.27%2.45%3.03%3.82%

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.75M21.43M15.99M30.53M80.70M23.00M
Total Liabilities7.90M10.91M6.95M11.63M18.02M23.25M
Total Equity1.86M10.52M9.03M19.30M62.76M-93.00K
Cash3.36M15.46M9.35M21.09M70.46M12.58M
Total Debt2.92M4.14M952.79K1.69M1.40M2.28M
Net Debt-440.56K-11.32M-8.40M-19.40M-69.06M-10.29M

Cash Flow

Currency: USD2015-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--11.08M-14.44M-29.42M-34.63M-61.24M-77.80M
Investing Cash Flow-5.99M-886.07K-992.57K-2.58M-2.28M-596.00K
Financing Cash Flow-1.46M27.42M23.27M49.34M112.83M20.55M
Capital Expenditure0222.45K582.24K1.67M2.39M2.27M1.95M
Free Cash Flow--11.30M-15.02M-31.08M-37.03M-63.51M-79.76M
FCF to OCF-102.01%104.03%105.66%106.92%103.70%102.51%

Earnings

Report DateNov 27, 2024Feb 26, 2025May 13, 2025Aug 11, 2025Nov 12, 2025Feb 26, 2026May 13, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate0.00-0.56-0.43-0.48-0.57-0.56-0.27-0.21-
EPS Actual-1.07-0.52-0.61-0.58-0.62-0.75-0.28-0.30-
Surprise-7.77%-41.86%-20.83%-8.77%-33.93%-2.74%-42.86%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hours-After-hours-

Key Statistics & Ratios

Market Cap745.56M
Enterprise Value489.09M
Trailing P/E0.00
Forward P/E0.00
Price / Sales332.54
Price / Book2.95
EPS-1.96
Book Value2.58
Revenue (TTM)2.24M
Gross Profit (TTM)1.68M
EBITDA-104.50M
Profit Margin0.00%
Operating Margin-3072.05%
Return on Equity-74.65%
Return on Assets-42.51%
Shares Outstanding97.46M
Shares Float65.98M
Beta0.73
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 15.33
  • Strong Buy
    3
  • Buy
    1

Ownership Breakdown

Institutions
71.03%
Insiders
16.48%
Retail / Other
12.49%

Top Institutional Holders

  • L1 Capital Pty Ltd
    7.79M7.99%
  • Sio Capital Management, LLC
    5.55M5.69%
  • Nantahala Capital Management, LLC
    5.53M5.68%
  • BlackRock Inc
    4.89M5.02%
  • ADAR1 Capital Management LLC
    3.79M3.89%
  • Perceptive Advisors LLC
    3.43M3.51%
  • RA Capital Management, LLC
    3.00M3.08%
  • Bvf Inc
    3.00M3.08%
  • FMR Inc
    2.90M2.98%
  • Ensign Peak Advisors Inc
    2.09M2.14%
  • Geode Capital Management, LLC
    1.84M1.89%
  • Rhenman Partners Asset Management AB
    1.54M1.58%
  • UBS Group AG
    1.41M1.44%
  • State Street Corp
    1.22M1.25%
  • Vestal Point Capital LP
    1.14M1.17%
  • Affinity Asset Advisors, LLC
    912.40K0.94%

Top Fund Holders

  • iShares Russell 2000 ETF
    2.11M2.16%
  • Fidelity Pacific Basin
    1.80M1.84%
  • Rhenman Healthcare Equity L/S RC2 SEK
    1.44M1.48%
  • Fidelity Small Cap Index
    886.81K0.91%